ADC Deal Trends 2026: What's Driving Record Licensing Values

Antibody-drug conjugates have become the most aggressively pursued modality in biopharma licensing. In 2025 alone, ADC deals accounted for over $45 billion in total disclosed deal value, and 2026 is on track to exceed that figure before mid-year. For deal teams, understanding the structural forces behind these valuations is no longer optional — it is table stakes.

The Structural Shift in ADC Valuations

Three years ago, ADC deals averaged $800M-$1.2B in total deal value for Phase 1 assets. Today, that range has shifted to $1.5B-$5B+, with select programs commanding upfronts exceeding $500M. This is not speculative enthusiasm — it reflects a fundamental change in the risk-reward calculus for large pharma acquirers.

The catalysts are well understood but worth restating. Enhertu (trastuzumab deruxtecan) demonstrated that a single ADC could address multiple solid tumor indications, creating a platform-level commercial opportunity. That proof point reshaped how acquirers model lifetime revenue for ADC assets. Where deal models previously assumed one or two indications, current valuations routinely incorporate four to six label extensions.

Upfront Payment Benchmarks

Our ADC deal benchmarks show that median upfront payments for Phase 1 ADC assets have increased 85% since 2023. The distribution has also widened: the 25th percentile upfront for a preclinical ADC is now $50M (vs. $15M three years ago), while the 75th percentile reaches $200M for programs with differentiated linker-payload technology.

For Phase 2 assets with solid tumor data, upfronts now routinely exceed $400M. This compresses the traditional phase-transition premium — acquirers are paying Phase 2 prices for Phase 1 assets when the target biology is validated and the payload class has precedent.

What Is Driving the Premiums?

Four factors are compounding to inflate ADC deal values beyond historical norms:

1. Platform scarcity. There are fewer than 20 companies globally with proprietary linker-payload platforms capable of producing next-generation ADCs. Large pharma is competing for a finite supply of partnership opportunities, and that competition shows up directly in deal terms.
2. Indication breadth. Modern ADCs increasingly demonstrate activity across tumor types. A single molecule with HER2, Trop-2, or Nectin-4 targeting can reasonably model $3B-$8B in peak sales across solid tumor indications. Deal models reflect this expanded commercial TAM.
3. Manufacturing de-risking. Contract manufacturing organizations have invested heavily in ADC production capacity. What was once a material development risk — complex conjugation chemistry, scale-up challenges — is now largely addressable. This removes a significant discount factor from risk-adjusted models.
4. Competitive urgency. Every major pharma company needs an ADC franchise. Those without one face pipeline gaps that cannot be filled through internal discovery on a competitive timeline. This urgency manifests as accelerated diligence timelines and pre-emptive offers.

Milestone Structures Are Evolving

Beyond upfronts, the structure of milestone payments in ADC deals has shifted. Traditional deals front-loaded regulatory milestones (IND, Phase 1 initiation, Phase 2 data). Current ADC deals increasingly weight milestones toward commercial events — first commercial sale, sales thresholds at $500M, $1B, and $2B — reflecting confidence that approved ADCs will achieve blockbuster status.

Royalty rates have also compressed upward. Where ADC royalties in 2022-2023 ranged from low-to-mid teens, current deals are closing at mid-teens to low-twenties, with tiered structures that escalate above $1B in net sales.

Implications for Deal Teams

If you are negotiating an ADC licensing deal in 2026, three dynamics should inform your strategy:

Benchmark against the current market, not historical averages. Using 2023 deal comps to anchor a 2026 negotiation will leave significant value on the table. The Ambrosia deal calculator provides current-year benchmarks calibrated to the most recent disclosed transactions.

Structure for indication optionality. ADC deals that grant worldwide, all-indication rights are commanding the largest total values. But biotech licensors should consider whether retaining rights to specific tumor types or geographies could yield greater long-term value, particularly if the asset demonstrates activity in indications where the licensor has existing commercial infrastructure.

Negotiate payload-platform economics separately. If your company has a proprietary payload platform (not just a single molecule), the deal should reflect that. Platform access rights, right-of-first-negotiation for follow-on molecules, and technology licensing fees are all mechanisms to capture the full value of the underlying technology.

What to Watch for the Rest of 2026

The ADC deal market shows no signs of cooling. Several Phase 2 readouts expected in Q2-Q3 2026 could catalyze the next wave of transactions. Bispecific ADCs — molecules that engage two targets simultaneously — represent the frontier, and early clinical data from this class will likely set new benchmarks for upfront payments if efficacy signals hold.

For a data-driven view of where ADC deal terms stand today, explore our ADC deal benchmarks page, which tracks upfront payments, milestones, royalties, and total deal values across all disclosed ADC transactions since 2018.